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Abstract: 
In the search for new sources of antimicrobials many researchers have investigated antimicrobial 
peptides (AMPs) as templates for the design of innovative therapeutics. However, efforts to 
develop AMPs in this area has been severely hampered by their inherent susceptibility to 
enzymatic degradation. Given this only a handful of AMPs are currently in clinical trials. Peptide 
mimetics such as peptoids have emerged as highly promising alternatives to AMPs as they are 
inherently stable to enzymatic degradation and display potent antimicrobial properties. This 
feature article highlights the progress that has been made towards the development of novel anti-
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1. Introduction  
The innate immune system provides an effective  first line of defence against infection and as such 
significant efforts have been directed towards exploiting the activities of antimicrobial peptides 
(AMPs), with a view to using them as templates for the design of innovative therapeutics.1–8 AMPs 
are typically less than 40 amino acids in size, are cationic in nature and they play an important role 
in host defence, operating as both antimicrobial agents and modulators of the inflammatory 
response.9,10 Their antimicrobial mode of action is typically based on the disruption of cellular 
membranes and as such the development of organism resistance is challenging. In the context of 
increasing antibiotic resistance, the antimicrobial and immunomodulatory actions of AMPs have 
some appeal for future treatment of infections.1,10 However, AMPs like all peptides are susceptible 
to degradation by proteinases particularly at wound and inflammatory sites4,11  thereby limiting 
their potential as novel therapeutics. Oligo N-substituted glycines (peptoids) are peptide isomers 
(Fig. 1) that combine many of the features of AMPs with the added advantage that they are resistant 
to proteinases.12 Peptoids display a range of diverse biological activities13 but a key area of 
expanding research interest is in their development as anti-infective agents.14 Their antibacterial 
activity (in the low μm range), selectivity for bacterial cells and low hemolytic activity are 






Fig. 1. Representative structure of the backbone of a peptide compared to a peptoid. 
 
In this feature article we review the recent advances made in the development of anti-infective 
peptoids. While a discussion about peptoid activity against bacteria, fungi and parasitic infections 
is presented this review predominately focuses on molecules that fall within the structural class of 
alpha peptoids rather than beta-peptoids15 or peptide-peptoid hybrids.16,17 
 
2. Antibacterial Peptoids 
Linear peptoids  
One of the earliest examples of anti-infective peptoids was reported by Barron in 2003.18 In this 
work a series of linear peptoid oligomers were designed to mimic the structural and physical 
properties of the well-studied cationic AMP, Magainin-2 Amide. An example of one of the 
oligomers prepared is (1) (Fig. 2) which is a linear peptoid comprised of 12 residues. (1) [H-(NLys-
Nspe-Nspe)4-NH2] contains a mixture of two monomers, Nspe, a peptoid monomer analog of Phe, 
and NLys, a peptoid monomer analog of Lys. Peptoid (1) was found to have low micromolar 
activity against both Gram-negative (Escherichia coli) and Gram-positive (Bacillus subtilis) 
bacterial strains and only 1.4% hemolysis was seen at the E. coli MIC (5.4 ±0.9 µM). The 
promising antibacterial properties observed for 1 were attributed to the fact that it had an overall 
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net positive charge, and a helical and facially amphipathic structure that resembled that of 







Fig. 2 Structures of a linear alpha peptoids developed by Barron and Zuckermann. analog of 
Magainin-2 amide [H-(NLys-Nspe-Nspe)4-NH2] (1), H-(NLys-Nssb-Nspe)4-NH2







A more comprehensive study that built on this early work was reported by Barron and Zuckermann 
in 2008.14 In this study a set of 15 linear peptoid analogs inspired by the structures of well-known 
cationic AMPs, such as melittin and also peptoid (1) were prepared and screened for biological 
activity against both Gram-negative (E. coli) and Gram-positive (B. subtilis).  10 of the 15 linear 
peptoids screened exhibited low-micromolar MICs against both E. coli and B. subtilis that were 
comparable to the AMPs also studied (melittin and pexiganan) (selected peptoids are presented in 
Table 1). The hemolytic properties of the peptoids were also determined along with an initial 
measure of selectivity (determined from the lytic activity of the peptoids against human 














Table 1 Early examples of linear peptoids with antibacterial properties.14 MIC: minimum 
inhibitory concentration. 












31 3.9 >3.9 
H-(NLys-Nspe-Nspe)2-NH2 (3) 
 
27 27 >8.1 
H-(NLys-Nspe-Nspe)5-NH2 (4) 
 
5.5 1.4 >0.55 
H-(NLys-Nrpe-Nrpe)4-NH2 (5) 
 
3.5 0.88 4.6 
H-(NGlu-Nspe-Nspe)4-NH2 (6) 
 









31 15 >3.9 
* Selectivity ratio, SR (HD10)/(E. coli MIC) 
 
Since this important study by Barron and Zuckermann was published several groups have made 
valuable contributions to the development of this field13,16 and a selection of examples of linear α-
peptoids with antibacterial properties are given in Fig. 3. As Table 2 highlights linear α-peptoids 
have been found to be effective against a range of both Gram-positive and Gram-negative bacteria 
with MIC values ranging from 0.5 to >500 µg/mL (1 µM to > 50 µM). While the structures of the 
linear peptoids 9-19 vary considerably in terms of their monomer composition, it is worth noting 
that all of the peptoids reported to have antibacterial properties are overall cationic in nature. The 
charge within the peptoid sequence can be provided via the inclusion of a monomer(s) with an 
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amine functionality (e.g. NLys, peptoids 9, 10, 15 and 16), a guanidine functionality (e.g. NhArg, 
peptoid 11), or a trimethylated ammonium (e.g. Naetm+, peptoid 13 or Nchtm+ peptoid 14). 
Examples where the positive charge within the peptoid is provided by more than one different type 
of cationic monomer (e.g. Fig. 3, peptoid 12) are less common in the literature but recent advances 
in the synthetic approaches to access such peptoids is likely to change this.19 At present it is not 
possible to draw any general conclusions as too which type of cationic monomer should be 
included to provide the most potent antibacterial properties and greatest SRs. This is due to the 
fact that the situation is highly complex given the number variables involved. For example, it has 
been found that that the position of the charged monomers within the peptoid sequence, the overall 
charge to hydrophobicity ratio and even the length of the side chain within the cationic monomer 
itself (e.g. NLys versus Nah) can all affect the biological properties.20 
While the sequence length can vary the majority of the antimicrobial peptoids reported in the 
literature are 8 to 12 residues long. However, work from Faure et al. (Fig. 3, peptoid 14, 6 
residues)21 and Seo et al. (Fig. 3, peptoid 16, 7 residues)22 have demonstrated that shorter linear 
peptoids can be designed to maintain potent antibacterial properties and a good SR. We have also 
shown that lipidation of linear peptoids is a tool that can also be used to good effect to access 
shorter linear peptoid sequences with good biological activity profiles. 23,24 
In terms of common structural features, it is also noteworthy that all of the linear peptoids reported 
are amphipathic, containing a mixture of both cationic and hydrophobic monomers. Just as for the 
cationic monomers a range of different hydrophobic monomers have been used in the design of 
linear antibacterial peptoids. The chiral aromatic monomer Nspe which can be used to reinforce 
the helical properties of a linear peptoid can be found in many of the reported sequences (Table 1, 
peptoid 1-8 and Fig. 3, peptoids 11-17). However, the inclusion of chiral residues is not essential 
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for activity and a range of peptoids that contain no chiral monomers (aromatic or aliphatic) have 
been found to have promising antibacterial properties (Fig. 3, peptoids 9 and 10). The presence of 
substituents on the aromatic ring of a monomer has also been found to modulate peptoid activity. 
In particular, the inclusion of halogen atoms has been found to have either positive or negative 
effects in terms of both antibacterial activity and toxicity profiles. A wide range of halogenated 
monomers are commercially available and have been explored (Fig. 3. peptoids 15 and 17). Both 
the Cobb group and those of Barron and Seo have reported that the inclusion of a fluorine atom on 
the aromatic ring of the monomer can enhance the biological activity of a linear α-peptoid 
compared to its non-fluorinated analog.22 The results seen for fluorinated monomers in these linear 
α-peptoid systems were mirrored in a corresponding study on α-peptide-β-peptoids that was 
carried out by Franzyk and Hansen.25 Interestingly, the inclusion of a chlorine atom on the aromatic 
ring of the monomer was found in both the studies carried out by Cobb and Barron and Seo to 
decrease the antibacterial activity observed. This is like to be due to the differences in hydrophobity 
that the inclusion of a F atom and Cl atom have on their respective monomers, and thus the linear 









Table 2 Selected examples of linear α-peptoids with antibacterial properties.  














32 µg/mL 64 µg/mL 33,35 
(NhArg-Nspe-Nspe)4 (11) 
 




17 µM 17 µM 19,20 
H-(Naetm+-Nspe-Nspe)4 -NH2 (13) 
 
50 µM 6.3 µM 21 
H-(Nchtm+-Nspe-Nspe)2 -NH2 (14) 
 
50 µM 3.1 µM 21 
H-[(NLys-
NpfbNpfb)(NLysNspeNspe)]2-NH2  (15) 
 
6 µM 2 µM 20 
H-(NLys-Nspe-Nspe)3-NLys-NH2 (16) 
 




>6.1 µM 6.1 µM 22 
H-(Nhe-Nspe-NLys)2-NH2 (18) 
 
n.a* n.a* 26 
*n.a = not active against these specifc organisms but activity was observed against 
Mycobacterium bovis BCG, the laboratory strain M. tuberculosis H37Rv and the MDR clinical isolate M. 
tuberculosis CSU87. Note – Only one representive Gram-negative and one Gram-positive baterium were 
selected and the data given in this table does not cover the full range of antibacterial properties exhibited 



































Fig. 3 Selected examples of linear α-peptoids with antibacterial properties.  
 
Similar to the development of new AMP based antibiotics a challenge in this area relates to the 
design of peptoid sequences where the selectivity ratios (SRs) are suitable for further development. 
The application of machine learning approaches have helped to enable the rationale design of 
AMPs with improved properties and SR’s but the application of such methods in the area of 
antimicrobial peptoid design has not been widely applied.27–29 One of the only examples of work 
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in this area was reported by Barron and Jenssen in 2016.30  In this work the authors were able to 
take 27 diverse peptoid sequences and use them to develop a new QSAR model, which could be 
used to correlate antimicrobial peptoid structure with antimicrobial activity. This study makes a 
valuable contribution to the field as it demonstrates the clear potential that machine learning 
approaches could offer in terms of the rationale design of anti-infective peptoids. A second more 
recent study in a related area was published by Lee et al. who used a training set derived from a 
series of AMPs to predict the bacterial membrane disruptive properties of several antibiotics. 
Within the compounds that were investigated in this study were a  series of cyclic peptoids 
developed by the Kirshenbaum group.31    
Being able to identify peptoid properties that peptoids have which  that could an be used as 
descriptors of biological activity, offers a route by which to rationally design new sequences for 
screening. The Cobb group have sought to correlate physical properties such as log D (distribution 
coefficient) with the biological data obtained for linear peptoids.32 It is likely that this area will see 
further activity in the future as new approaches to aid in the rationale and computational design of 
biological activity and selective linear peptoids are sought.  
A further area that is likely to influence and aid in the future design of more active and selective 
antibacterial linear peptoids is mode of action studies. Several groups have demonstrated that 
linear peptoids can cause bacterial cell membrane disruption ultimately leading to cell death.21,33–
35  Just like AMPs, the exact mechanisms by which this cellular membrane disruption occurs is 
likely to vary given factors such as peptoid length, charge and cationic/ hydrophobic ratios. It has 
recently been demonstrated that like some linear AMPs (e.g. Indolicidin)36 linear peptoids can also 
operate via an intracellular mode of action.37  While this later discovery is an exciting one and it 
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potentially offers a route by which to design more selective anti-infective peptoids the 
identification of more peptoids with intracellular modes of action will be needed.  
Lipopeptoids 
Lipopeptides such as polymyxin B, daptomycin, and caspofungin are valuable antimicrobial agents 
used in the clinic.  The earliest exploration of lipidating peptoids was done by the group of Annelise 
Barron.  This work indicated that relatively long (12-mer) antibacterial peptoids could be shortened 
and lipidated with long alkyl tails to retain antibacterial activity.38  Decreasing the overall size of 
peptoids simplifies synthesis and improves pharmacological properties.  Not surprisingly, both 
antibacterial efficacy and hemolytic activity increased as the alkyl tail was lengthened.  The most 
promising compound from this initial study, C134mer (19)(Fig.4)  was later shown to be effective 
against M. tuberculosis and P. aeruginosa biofilms with MIC values ranging from 6-25 µM.39,40  
Additionally, the Schweizer group explored a series of guanidylated lipopeptoids that showed 







Fig.4 Examples of lipopeptoids with antibacterial activity. C134mer (19), an early lipopeptoid with 
activity against M. tuberculosis and P. aeruginosa biofilms. K15 (20), a lipopeptoid identified by 
the PLAD assay with activity against the ESKAPE bacteria.  
 
Inspired by these seminal explorations, the Bicker lab utilized a high-throughput Peptoid Library 
Agar Diffusion (PLAD) assay to identify antibacterial lipopeptoids from combinatorial libraries.  
Screening of a relatively small library resulted in a lipotripeptoid, K15 (20) (Fig. 4), with modest 
antibacterial efficacy against the ESKAPE pathogens.42  Further study interrogated the relationship 
between alkyl tail length, antibacterial efficacy, and mammalian cytotoxicity using K15 (20).  This 
work indicated that increased alkyl tail length was necessary for antibacterial activity but also 
increased cytotoxicity and hemolytic activity, confirming earlier studies.23  However, alkyl tail 
length was not solely responsible for cytotoxicity and hemolytic activity and we realized that these 
toxic effects could be mitigated by increasing the hydrophilicity of lipopeptoid monomers.  This 
work also indicated that lipidation of short peptoid libraries improved hit rate and identification of 
antibacterial compounds during PLAD screening. Our most recent study in this field explored the 
conversion of antimicrobial lipopeptides into lipopeptoids.24  Peptoid mimics had similar or 
slightly diminished antimicrobial activity, an improved toxicity profile, and excellent proteolytic 




Cyclic peptoids are of interest as antimicrobials because they are conformationally ordered, more 
rigid, and have better cell permeability than linear peptoids.43  An early study demonstrated that 
cyclization of peptoids improved antibacterial and antifungal activity compared to linear 
counterparts regardless of monomer composition.44 The further development of antibacterial cyclic 
peptoids was spearheaded by Kent Kirshenbaum’s group over the past several years.  A seminal 
study from Kirshenbaum et al. showed that macrocyclization of amphiphilic peptoids improved 
antibacterial activity by as much as eight fold.45  Furthermore, these compounds were effective 
against both Gram-positive and Gram-negative bacteria with MIC values ranging from 0.5 to >500 
µg/mL depending on macrocycle size and composition and importantly had relatively little 
hemolytic activity.  Follow-up studies by Kirshenbaum et al. indicated that some macrocyclic 
peptoids were efficacious and selective for clinical strains of methicillin resistant Staphylococcus 
aureus (MRSA), exerting antibacterial activity through membrane pore formation.46  One 
compound in particular, C124 (21)(Fig. 5), had an MIC against MRSA of 3.9 µg/mL and 32 to 45-
fold selectivity for MRSA over mammalian cells.  Further detailed studies using electron 
microscopy and X-ray scattering analysis of Langmuir monolayers indicated that peptoid 
macrocyclization improved membrane permeation47 and that tuning hydrophobicity could control 




Fig. 5. Structure of cyclic peptoid, C124 (21), with selective antibacterial activity against 
methicillin resistant Staphylococcus aureus. 
 
3. Antifungal Peptoids 
Nearly all research into antifungal peptoids has focused on identifying compounds with efficacy 
against Candida albicans and Cryptococcus neoformans, two yeast like pathogens responsible for 
most fungal infections in humans.  C. albicans, the leading fungal pathogen in hospital originated 
infections, primarily infects mucosal surfaces and can lead to invasive candidiasis, a dangerous 
blood borne infection.49  C. neoformans principally infects immunocompromised individuals, 
originating as a pulmonary infection that leads to deadly cryptococcal meningitis if left untreated.50  
An early report evaluated the antimicrobial activity of lysine rich peptoid-peptide hybrids effective 
against both C. albicans and C. neoformans with MICs ranging from ≤1.6 to 12.5 µg/mL.51  The 
Franzyk group also evaluated a series of hybrids, specifically β-peptoid-peptide hybrids, against 
C. albicans with modest efficacy and low hemolytic activity, though these compounds exhibited 
better antibacterial that antifungal efficacy.15  Around the same time, Barron et al. demonstrated 
the antifungal activity of relatively short lipopeptoids incorporating pentyl, decyl, and tridecyl 
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tails.38  Anti-Candida activity was generally improved with the addition of longer alkyl tails.  
Intrigued by these results, the groups of Riccardis and Izzo explored the synthesis and antifungal 
activity of cyclic peptoids.44  Amphipathic and N-lysine rich cyclic peptoids were more effective 
against C. albicans and C. neoformans than bacterial pathogens, with minimal hemolytic activity.  
Additionally, cyclic compounds were more effective than their linear counterparts regardless of 
the microbe tested.  While the focus of most antifungal peptoid studies has been human pathogens, 
the antifungal efficacy of peptoids against plant pathogens has also been explored, namely against 
Fusarium virguliforme and Fusarium lateritium.52   
Relatively little is known regarding the mechanism of action for antifungal peptoids.  It is 
hypothesized that most peptoids exert antimicrobial activity through membrane disruption, 
analogous to AMPs, though intracellular targets are possible.  Being eukaryotes, fungi and 
mammalian cells share similar membrane compositions, making antifungal selectivity challenging 
for compounds exerting their effects via the membrane.  One early study on anti-Candida peptoids 
indicated that cells exposed to these compounds decreased phenotypic switching to the pathogenic 
hyphal phenotype and displayed marked cellular and organellular stress, suggesting a possible 
intracellular target.53 
The most recent efforts in antifungal peptoids have come from our own labs, focusing on C. 
albicans biofilms (Cobb) and C. neoformans (Bicker).  Most clinical infections of bacteria and 
fungi exist in biofilm form, often resulting in resistance to antimicrobials that are effective against 
planktonic microbes. Additionally, biofilms are rarely monospecial but often exist polymicrobially 
and can include both bacterial and fungal pathogens, resulting in synergistic sensing, growth, and 
resistance.  Cobb and Lundy sought to explore the utility of peptoids as anti-biofilm agents while 
developing a novel modified quantitative PCR method for evaluating cross-kingdom biofilm 
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viability.54  Unlike traditional methods of biofilm quantification, the modified qPCR method 
allows researchers to detect viable but non-culturable microbes as well as delineate the viability of 
different species in a polymicrobial biofilm.  From this study, peptoid 17 (22) (Fig. 6) was the 
most effective anti-biofilm peptoid against monospecial and cross-kingdom polymicrobial 
biofilms of C. albicans, S. aureus, and E. coli at concentrations as low as 10 µM.  Additionally, 
this peptoid had no observable cytotoxicity below 100 µM and data suggest peptoid 17 (22) exerts 
its antifungal effects through membrane disruption, which would decrease the likelihood of 
antifungal resistance development.  This was the first study demonstrating peptoid efficacy against 
fungal biofilms, an important step towards developing peptoids as antifungal therapeutic agents. 
 
Fig. 6 Structures of the most recent antifungal peptoids, including Peptoid 17 (22) effective against 
cross-kingdom polymicrobial biofilms, as well as AEC5 (23) and β-5 (24) effective against C. 
neoformans. 
 
The Bicker lab adapted a high-throughput phenotypic screen, known as the Peptoid Library Agar 
Diffusion (PLAD) assay, toward identifying antifungal peptoids against C. neoformans from 
combinatorial libraries.55  One lipotripeptoid, termed AEC5 (23)(Fig. 6), had an MIC of 6.25 
µg/mL against C. neoformans H99S, as well as efficacy against clinical strains of C. neoformans 
and C. gattii, a more virulent cryptococcal strain capable of infecting immunocompetent 
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individuals.  Additionally, AEC5 (23) demonstrated minimal toxicity against several mammalian 
cell lines, giving a reasonable lead compound for further development.  In an effort to contribute 
valuable preclinical information on antifungal peptoids we characterized some pharmacokinetic 
and therapeutic parameters of AEC5 (23).  Namely, we determined that this peptoid kills C. 
neoformans rapidly (~50% reduction in 30 minutes; complete killing in 3 hours), has an excellent 
in vivo half-life of 20+ hours, and was not toxic during a 28-day sub-chronic study with daily doses 
of AEC5 as high as 50 mg/kg in mice.56  Concomitantly, we undertook an iterative structure-
activity relationship study to improve the selectivity of AEC5 by individually optimizing the 
peptoid monomers.  Slight modifications to AEC5, namely substituting a thiophene into the third 
position and trimethylating the N-lysine derivative in the second position resulted in peptoid β-5 
(24) (Fig. 6) with improved efficacy against C. neoformans and decreased toxicity against human 
hepatic cells.57  Taken together, the most recent data on antifungal peptoids indicate that they could 
supplement the small collection of clinically used antifungal agents wrought with resistance and 
toxicity issues. 
4. Antiparasitic peptoids 
 
Research efforts from our own group (Cobb)6,7 and others58 have identified AMPs derived from 
amphibians as potential anti-parasitic compounds. A wide variety of other AMPs derived from 
mammalian sources, invertebrates, or synthetic AMPs have been shown to have activity against 
protozoan species.59  In contrast and despite the encouraging results reported on the antibacterial 
properties of peptoids very few groups have sought to investigate the effects of peptoids against 
protozoan parasites. An early study from Olsen et al. tested α-peptide β-peptoid chimeras against 
Plasmodium falciparum, the causative agent of malaria. For some sequences within this study, 
sub-hemolytic doses showed promising anti-plasmodial activities.60 Short linear peptoids have 
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also been found to be inhibitors of trypanothione reductase, an enzyme vital to both Trypanosoma 
and Leishmania species.61 Recently, work in our group (Cobb) has focused upon the anti-parasitic 
action of linear peptoids against Leishmania mexicana, the causative agent of cutaneous 
leishmanaisis (CL).62,63 In these structure activity investigations, some key factors for anti-
Leishmanial activity against the amastigote (clinically relevant form) of the parasite have been 
identified (Fig. 7, Peptoids 15, 25-27). In a given series of linear peptoids anti-parasitic activity 
increased as the chain length was increased from 6 monomers to 12 monomers.62 In addition the 
inclusion of a fluorine atom on the aromatic monomers used within a sequence (e.g. Fig, 7, Peptoid 
15) led to an increase in the anti-Leishmanial when compared to the analogous non-fluorinated 
systems. Interestingly, it was also found that peptoids such as 27 (Fig. 7), where the overall charge 
had been reduced to +2 were found to have more potent anti-Leishmanial activity compared to 
their corresponding +4 analogs. This result is the opposite of what is typically seen in studies 
carried out to design potent antibacterial peptoids where an increase in cationic properties and 
overall net charge generally results in increased biological properties.  In addition, it was also 
found that in the libraries of linear peptoids screened most were less active against the axenic 
amastigote forms of the L. mexicana parasite. This result mirrors what is commonly seen with 
linear AMPs tested against leishmania spp. and the differences in anti-parasitic activity between 
the different parasite life stages provides evidence that the linear α-peptoids studied are exerting 
their mode of action via membrane disruption. However, more work is needed to confirm if this is 
actually the case. As part of our work in this area we have also been able to design a peptoid 






Fig. 7 Representative structures of linear peptoids 15, 25-27, with activity against L. mexicana. 
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5. Conclusions andFuture outlook 
Peptoids with antimicrobial activity against a host of pathogens from different kingdoms have been 
developed over the past many years. While peptoids offer many advantages over AMPs or classical 
antibiotics, we highlight below some of the challenges that remain in the transition of antimicrobial 
peptoids to the clinical space.  An important measure of a compound’s therapeutic value is the 
selectivity ratio (SR) or therapeutic index (TI).  SR is calculated as the toxicity value divided by 
the antimicrobial efficacy (e.g., SR = TD50/MIC) and serves as a measure of the selectivity of a 
compound.  SR values greater than 10 are characteristic of lead molecules but much higher SR 
values must be achieved for clinically relevant antimicrobial compounds. As shown in Table 1, 
early antibacterial linear peptoids developed by Barron had SR values ranging from 8 to <1.14  
Initial antifungal lead peptoids developed by the Bicker lab had SR values around 10 and were 
improved to >30 through iterative SAR studies.57  Initial antiparasitic peptoids developed by the 
Cobb group had SR values ranging from 2.4 to 6.62  Exploring expanded chemical space yielded 
peptoids with improved antiparasitic activity, but increased toxicity as well, limiting SR values to 
1 or less.63  In general, peptoid toxicity towards mammalian cells increases with increasing 
antimicrobial activity, regardless of pathogen.  However, there has been a focus in recent years to 
understand this correlation and develop antimicrobial peptoids with higher SR values.  One 
particular phenomenon observed by our  labs and others is the unique correlation between toxicity 
and side-chain length for cationic residues.17,20,57  Cationic monomers with longer side chains (i.e., 
five or six methylenes) have increased toxicity compared to the monomer with four methylenes 
(NLys) due to increased C-H group hydrophobicity.  Interestingly, as side chains are shortened to 
three or two methylenes, hydrophobicity and toxicity increase.  The exact reason for this remains 
unknown, though it could be due to loss of entropic freedom or depression of pKa as the cationic 
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group approaches the amide backbone.  Through these explorations, antimicrobial peptoids with 
excellent SR values have been identified, namely “Peptoid 7” (Fig. 3, Peptoid 16 in this article) 
identified by Seo and Barron with an SR of approximately 5022 and peptide/peptoids hybrids 
identified by Franzyk with SR values >100.17  Additionally, one of the cyclic peptoids identified 
by Kirshenbaum had modest toxicity, possessing SR values >32.46  The SR value of antimicrobial 
peptoids must increase for them to gain clinical traction and factors that contribute to peptoid 
toxicity remain an area for continued exploration. 
 Literature indicates that the major driver of mammalian cytotoxicity in antimicrobial 
peptoids is overall compound hydrophobicity.17,20  In lipopeptoids the majority of this hydrophobic 
character comes from the aliphatic tail.  Efforts from the Bicker lab to reduce toxicity of 
lipopeptoids by shortening the aliphatic tail concomitantly lead to a decrease in antimicrobial 
activity.23,57  Similar studies early on by the Barron lab had the same results.38  Yet one thing we 
realized in our studies was that the toxicity of the aliphatic tail could be mitigated by using more 
hydrophilic monomers while still retaining antimicrobial activity.  The chemical diversity of 
antimicrobial peptoids reported in the literature is somewhat limited.  Most compounds are 
composed of the monomers S-phenylethylamine (Nspe), benzylamine (Nphe), and length 
derivatives of the cationic 1,4-diaminobutane (NLys).  Though these have proven useful, the path 
forward to clinical antimicrobial peptoids will undoubtedly require us to explore greater chemical 
diversity.  High-throughput screening using the Peptoid Library Agar Diffusion (PLAD) assay has 
allowed the Bicker lab to rapidly interrogate the antimicrobial utility of nontraditional 
monomers.42,55  Following the discovery of an antifungal peptoid containing a furan monomer and 
subsequent optimization to a thiophene, our lab continues to explore the utility of aromatic 
heterocycles.  The Cobb, Barron/Seo and Franzyk groups have all explored halogenated aromatic 
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monomers with particular success using fluorinated derivatives (e.g. Peptoid 15 in Table 2 and 
Fig. 3).20,25  The primary method for synthesizing peptoids allows for the incorporation of a 
tremendous number of monomers and the continued exploration of this chemical space and the 
development of new monomers64–66 will be key in developing more effective and selective 
antimicrobial peptoids. 
 Peptoids are generally thought to exert antimicrobial activity through non-specific 
membrane disruption and permeabilization, much like their natural peptide counterparts.14,67  
Membrane disruption may occur through depolarization or insertion into the membrane, causing a 
change in membrane fluidity that leads to leakage of cytoplasmic components.  Andreev et al. 
recently demonstrated that insertion of cyclic peptoids into bacterial membranes resulted in pore 
formation.48  A common technique for investigating membrane disruption is Live/Dead staining.  
In this assay, a membrane permeable dye is used to visualize live cells while a dye only capable 
of traversing compromised membranes before intercalating into DNA and fluorescing is used to 
indicate dead cells.  Though direct membrane permeabilization would result in increased “dead” 
staining, so would a mechanism of action with intracellular targets that triggers rapid cell death.  
Therefore, Live/Dead staining is best followed with other assays to confirm membrane disruption, 
such as liposomal assays and visualization of damaged membranes by electron microscopy.  A 
recent study by Mojsoska et al. nicely demonstrated this series of techniques to conclude that 
peptoids with different structural properties exhibit differing degrees of membrane disruption.33  
Additionally, this study showed that peptoids may work by both membrane disruption and binding 
of intracellular targets that disrupt protein or DNA synthesis.  Recent studies by the Hansen group 
showed that peptide/peptoid hybrids exerted antimicrobial activity through membrane disruption 
at higher compound concentrations while inhibiting cell wall biosynthesis at sub-MIC 
27 
 
concentrations.34,68  Studies into antifungal or antiparasitic peptoids suggest a membrane 
disruption mechanism of action, yet remain somewhat inconclusive and require further study.56 
Though the traditional mechanistic model for antimicrobial peptoids remains membrane 
disruption, these studies from the past few years highlight the need for detailed study into the 
mechanism of action for newly discovered antimicrobial peptoids, which may use more complex 
mechanisms of pathogen killing. 
 One last frontier that we identify as being poised to contribute to this field is the use of 
machine learning and predictive modeling.  Two studies have reported in silico characterization 
and modeling of antimicrobial peptoids. The first by Czyzewski et al. used a set of Peptoid 1 (1) 
(Fig. 2) derivatives to build a training set capable of predicting antimicrobial activity based on 
compound structure.30  Using this training set they were able to predict an MIC against E. coli very 
similar to the experimental MIC for Peptoid 1 (1).  A second study by Lee et al. used an 
antimicrobial peptide training set to predict the bacterial membrane disruptive properties of several 
antibiotics, including cyclic peptoids developed by the Kirshenbaum group.31  These studies 
demonstrate the utility of computer models in relating peptoid structure to antimicrobial activity 
and could be beneficial in the exploration of new peptoid monomers and efforts to improve SR 
values.  However, accurate computer modeling relies on sizeable data training sets.  As groups 
from around the world continue to explore the antibacterial, antifungal, and antiparasitic activity 
of peptoids, collaborative efforts to share and assemble data will be critical in using machine 
learning to propose and predict the physicochemical properties of antimicrobial peptoids that could 






Nearly 30 years since their initial development, peptoids remain an exciting source of promising 
antimicrobial agents.  Within these feature article we have highlighted the progress made by our 
groups and others over the past several years into peptoids with antibacterial, antifungal, and 
antiparasitic properties.  Notable progress has been made recently in exploring new monomers, 
relating peptoid structure to function, and broadening the scope of targeted pathogens. The 
research of our individual groups has focused on antiparasitic (Cobb) and antifungal (Bicker) 
peptoids, while both continuing to explore antibacterial peptoids as well. We are thankful for the 
opportunity to share progress from our own groups among others doing impactful research in this 
field.  However, we hope that inclusion of a future outlook perspective will inspire readers to 
participate in this field, working to address the challenges remaining in the push to bring an 
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